|
|
Sangamo Therapeutics, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: From ir"There is no impact to operating expense guidance or cash runway as a result of these collaborations ending" huh... Reimbursed R&D from BIIB and NVS was~$20M in each of the last two years... so now in 2023, there will be no reduction in spending but there will be $20M less cash inflows from that research reimbursement... yet Sangamo thinks that is "no change" |
||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 171662 | Re: From ir | nocashonhand | 0 | 3/23/2023 4:58:46 PM |
